{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:56:14Z","timestamp":1792364174655,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>mpMRI is routinely used to stratify the risk of clinically significant prostate cancer (csPCa) in men with elevated PSA values before biopsy. This study aimed to calculate a multivariable risk model incorporating standard risk factors and mpMRI findings for predicting csPCa on subsequent prostate biopsy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from 677 patients undergoing mpMRI ultrasound fusion biopsy of the prostate at the TUM University Hospital tertiary urological center between 2019 and 2023 were analyzed. Patient age at biopsy (67 (median); 33\u201388 (range) (years)), PSA (7.2; 0.3\u2013439 (ng\/ml)), prostate volume (45; 10\u2013300 (ml)), PSA density (0.15; 0.01\u20138.4), PI-RADS (V.2.0 protocol) score of index lesion (92.2% \u22653), prior negative biopsy (12.9%), suspicious digital rectal examination (31.2%), biopsy cores taken (12; 2\u201322), and pathological biopsy outcome were analyzed with multivariable logistic regression for independent associations with the detection of csPCa defined as ISUP\u2009\u2265\u20093 (<jats:italic>n<\/jats:italic>\u2009=\u2009212 (35.2%)) and ISUP\u2009\u2265\u20092 (<jats:italic>n<\/jats:italic>\u2009=\u2009459 (67.8%) performed on 603 patients with complete information.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Older age (OR: 1.64 for a 10-year increase; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), higher PSA density (OR: 1.60 for a doubling; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), higher PI-RADS score of the index lesion (OR: 2.35 for an increase of 1; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and a prior negative biopsy (OR: 0.43; <jats:italic>p<\/jats:italic>\u2009=\u20090.01) were associated with csPCa.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>mpMRI findings are the dominant predictor for csPCa on follow-up prostate biopsy. However, PSA density, age, and prior negative biopsy history are independent predictors. They must be considered when discussing the individual risk for csPCa following suspicious mpMRI and may help facilitate the further diagnostical approach.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-04991-6","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T16:04:32Z","timestamp":1714752272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Predicting clinically significant prostate cancer following suspicious mpMRI: analyses from a high-volume center"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-2595","authenticated-orcid":false,"given":"Matthias","family":"Jahnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Hausler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin H.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna P.","family":"Ankerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Herkommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"issue":"1","key":"4991_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J et al (2019) A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol 76(1):43\u201351","journal-title":"Eur Urol"},{"issue":"3","key":"4991_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","volume":"68","author":"R Arnsrud Godtman","year":"2015","unstructured":"Arnsrud Godtman R et al (2015) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the G\u00f6teborg randomized population-based prostate cancer screening trial. Eur Urol 68(3):354\u2013360","journal-title":"Eur Urol"},{"issue":"2","key":"4991_CR3","first-page":"B5327","volume":"64","author":"L Boesen","year":"2017","unstructured":"Boesen L (2017) Multiparametric MRI in detection and staging of prostate cancer. Dan Med J 64(2):B5327","journal-title":"Dan Med J"},{"key":"4991_CR4","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023"},{"issue":"6","key":"4991_CR5","first-page":"567","volume":"69","author":"F Monni","year":"2017","unstructured":"Monni F et al (2017) Magnetic resonance imaging in prostate cancer detection and management: a systematic review. Minerva Urol Nefrol 69(6):567\u2013578","journal-title":"Minerva Urol Nefrol"},{"issue":"3","key":"4991_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ et al (2020) Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis. Eur Urol 78(3):402\u2013414","journal-title":"Eur Urol"},{"issue":"4","key":"4991_CR7","first-page":"Cd012663","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost FH et al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4(4):Cd012663","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4991_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re O et al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20(1):100\u2013109","journal-title":"Lancet Oncol"},{"issue":"4","key":"4991_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M et al (2019) Head-to-head comparison of Transrectal Ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75(4):570\u2013578","journal-title":"Eur Urol"},{"issue":"5","key":"4991_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euo.2020.12.004","volume":"4","author":"E Mazzone","year":"2021","unstructured":"Mazzone E et al (2021) Positive predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and Meta-analysis. Eur Urol Oncol 4(5):697\u2013713","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"4991_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41391-021-00417-1","volume":"25","author":"B Oerther","year":"2022","unstructured":"Oerther B et al (2022) Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis 25(2):256\u2013263","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"4991_CR12","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.eururo.2017.03.039","volume":"72","author":"JP Radtke","year":"2017","unstructured":"Radtke JP et al (2017) Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer-patient-tailored risk stratification can reduce unnecessary biopsies. Eur Urol 72(6):888\u2013896","journal-title":"Eur Urol"},{"issue":"10","key":"4991_CR13","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00345-022-04118-9","volume":"40","author":"MA Rodr\u00edguez Cabello","year":"2022","unstructured":"Rodr\u00edguez Cabello MA et al (2022) Diagnostic evaluation and incorporation of PSA density and the prostate imaging and data reporting system (PIRADS) version 2 classification in risk-nomograms for prostate cancer. World J Urol 40(10):2439\u20132450","journal-title":"World J Urol"},{"issue":"2","key":"4991_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP et al (2018) A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol 74(2):197\u2013203","journal-title":"Eur Urol"},{"issue":"6","key":"4991_CR15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/cancers14061589","volume":"14","author":"J Morote","year":"2022","unstructured":"Morote J et al (2022) The Barcelona predictive model of clinically significant prostate cancer. Cancers (Basel) 14(6):1589","journal-title":"Cancers (Basel)"},{"issue":"12","key":"4991_CR16","doi-asserted-by":"publisher","first-page":"831.e19","DOI":"10.1016\/j.urolonc.2021.06.004","volume":"39","author":"NN Wang","year":"2021","unstructured":"Wang NN et al (2021) The Stanford prostate cancer calculator: development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer. Urol Oncol 39(12):831.e19-831.e21","journal-title":"Urol Oncol"},{"key":"4991_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.euros.2022.04.017","volume":"41","author":"S Parekh","year":"2022","unstructured":"Parekh S et al (2022) The Mount Sinai prebiopsy risk calculator for predicting any prostate cancer and clinically significant prostate cancer: development of a risk predictive tool and validation with advanced neural networking, prostate magnetic resonance imaging outcome database, and European randomized study of screening for prostate cancer risk calculator. Eur Urol Open Sci 41:45\u201354","journal-title":"Eur Urol Open Sci"},{"issue":"7","key":"4991_CR18","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00330-013-2795-0","volume":"23","author":"F Bratan","year":"2013","unstructured":"Bratan F et al (2013) Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 23(7):2019\u20132029","journal-title":"Eur Radiol"},{"issue":"5","key":"4991_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","volume":"75","author":"DC Johnson","year":"2019","unstructured":"Johnson DC et al (2019) Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol 75(5):712\u2013720","journal-title":"Eur Urol"},{"issue":"2","key":"4991_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","volume":"75","author":"AR Alberts","year":"2019","unstructured":"Alberts AR et al (2019) Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European randomized study of screening for prostate cancer risk calculators. Eur Urol 75(2):310\u2013318","journal-title":"Eur Urol"},{"issue":"2","key":"4991_CR21","first-page":"105","volume":"85","author":"M Boschheidgen","year":"2023","unstructured":"Boschheidgen M et al (2023) Multiparametric magnetic resonance imaging in prostate cancer screening at the age of 45 years: results from the first screening round of the PROBASE trial. Eur Urol 85(2):105\u2013111","journal-title":"Eur Urol"},{"issue":"3","key":"4991_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.prnil.2023.07.001","volume":"11","author":"JY Kim","year":"2023","unstructured":"Kim JY et al (2023) How to avoid prostate biopsy in men with prostate image-reporting and data system 3 lesion? Development and external validation of new biopsy indication using prostate health index density. Prostate Int 11(3):167\u2013172","journal-title":"Prostate Int"},{"issue":"10","key":"4991_CR23","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s00345-023-04564-z","volume":"41","author":"M Jahnen","year":"2023","unstructured":"Jahnen M et al (2023) Does experience change the role of systematic biopsy during MRI-fusion biopsy of the prostate? World J Urol 41(10):2699\u20132705","journal-title":"World J Urol"},{"issue":"2","key":"4991_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1148\/radiol.2021204112","volume":"300","author":"D Deniffel","year":"2021","unstructured":"Deniffel D et al (2021) Avoiding unnecessary biopsy: MRI-based risk models versus a PI-RADS and PSA density strategy for clinically significant prostate cancer. Radiology 300(2):369\u2013379","journal-title":"Radiology"},{"issue":"11","key":"4991_CR25","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1007\/s00330-022-08822-3","volume":"32","author":"D Deniffel","year":"2022","unstructured":"Deniffel D et al (2022) Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. Eur Radiol 32(11):7544\u20137554","journal-title":"Eur Radiol"},{"key":"4991_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00729-4","author":"Q Wu","year":"2023","unstructured":"Wu Q et al (2023) Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00729-4","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"4991_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen AC et al (2020) Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate Cancer Disease-focused panel. Radiology 296(1):76\u201384","journal-title":"Radiology"},{"issue":"3","key":"4991_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2214\/AJR.22.27421","volume":"219","author":"BR Salka","year":"2022","unstructured":"Salka BR et al (2022) Effect of prostate MRI interpretation experience on PPV using PI-RADS version 2: a 6-year assessment among eight fellowship-trained radiologists. AJR Am J Roentgenol 219(3):453\u2013460","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"4991_CR29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jacr.2021.02.032","volume":"18","author":"MS Davenport","year":"2021","unstructured":"Davenport MS et al (2021) Prostate imaging and data reporting system version 2 as a radiology performance metric: an analysis of 18 abdominal radiologists. J Am Coll Radiol 18(8):1069\u20131076","journal-title":"J Am Coll Radiol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04991-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04991-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04991-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:29:49Z","timestamp":1735853389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04991-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4991"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04991-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthias Jahnen, Tanja Hausler, Donna P. Ankerst, Michael W. Kattan, Kathleen Herkommer, Valentin H. Meissner, J\u00fcrgen E. Gschwend have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Technical University of Munich.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"290"}}